1. Acute promyelocytic leukemia (APL) in very old patients: real-life behind protocols
- Author
-
Giulio Trapè, Salvatore Perrone, Roberto Latagliata, Emilia Scalzulli, Carmelo Gurnari, Maria Teresa Voso, Malgorzata Monika Trawinska, Maurizio Martelli, Giuseppe Avvisati, Serena Rosati, Enrico Montefusco, Gioia Colafigli, Vincenza Martini, Clara Minotti, Giuseppe Cimino, Agostino Tafuri, Ida Carmosino, Ombretta Annibali, and Massimo Breccia
- Subjects
Acute promyelocytic leukemia ,medicine.medical_specialty ,Tretinoin ,elderly patients ,Group A ,Group B ,Leukemia, Promyelocytic, Acute ,real-life data ,Acute promyelocytic leukemia apl ,Internal medicine ,Induction therapy ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Retrospective Studies ,Old patients ,business.industry ,Remission Induction ,Retrospective cohort study ,Hematology ,General Medicine ,Settore MED/15 ,medicine.disease ,all-trans retinoic acid ,arsenic trioxide ,Treatment Outcome ,Oncology ,Cohort ,business - Abstract
BACKGROUND Acute promyelocytic leukemia (APL) is uncommon among subjects aged ≥ 70 years and the better therapeutic strategy represents an unmet clinical need. MATERIALS AND METHODS This prompted us to explore our real-life data on a retrospective cohort of 45 older APL patients (≥ 70 years) consecutively diagnosed at eight different hematologic institutions in Latium, Italy, from July 1991 to May 2019. RESULTS Two patients (4.4%) died from early hemorrhagic complications before treatment could begin. Twenty-two patients (51.1%) (Group A) were enrolled or treated according to standard clinical protocols, while 21 (48.8%) (Group B) received an ATRA-based personalized approach due to poor performance status. Morphologic complete remission (CR) after induction therapy was achieved in 33 patients (76.7%) with 100% of patients in Group A and 52.3% in Group B (p
- Published
- 2021